Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Phoenix, Arizona 85013


Cotara® is an experimental new treatment that links a radioactive isotope (iodine 131) to a targeted monoclonal antibody. This monoclonal antibody is designed to bind tumor cells and deliver radiation directly to the center of the tumor mass while minimizing effects on normal tissues. Cotara® thus literally destroys the tumor "from the inside out". This may be an effective treatment for glioblastoma multiforme, a malignant type of brain cancer.

Study summary:

To confirm the safety and tolerability of the Maximum Tolerated Dose (MTD) of 131I-chTNT-1/B MAb given as a single interstitial infusion in patients with glioblastoma multiforme at first relapse. To estimate overall survival, progression free survival and proportion of patients alive at six months after treatment.


Inclusion Criteria: - Histologically confirmed GBM - Clinical Target Volume between 5 and 60 cc (inclusive) - 18 to 75 years old (inclusive) - Karnofsky Performance Status ≥ 70 percent - If on steroids dose (± 4mg/day) must be stable for at least two weeks prior to screening/baseline visit. If not on steroids for two weeks prior to screening/baseline visit are allowed - Adequate hematology - Adequate renal function - Adequate liver function Exclusion Criteria: - Infratentorial tumor(s), tumor(s) that communicate with the ventricles or intraventricular disease - Bilateral non-contiguous gadolinium enhancing tumor - Diffuse disease (i.e., any satellite lesions less than 1.5 cm from anticipated location of any catheter tip or less than two satellite lesions) - Known or suspected allergy to study medication or iodine - Surgical procedure within four weeks of baseline - More than one prior chemotherapy regime or chemotherapy within four weeks (nitrosourea-based within six weeks) of baseline - Radiation therapy within four weeks of baseline - Investigational agent within last 30 days - Previous treatment with any chimeric monoclonal antibody - HIV positive - Evidence of active hepatitis



Primary Contact:

Principal Investigator
Deepak K Gupta, MBBS,MS,MCh
All India Institute of Medical Sciences, New Delhi

Backup Contact:


Location Contact:

Phoenix, Arizona 85013
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.